Population-based cohort study identifies better treatment objectives for women with advanced-stage ovarian cancer. Toxicity management and quality of life should be prioritized over treatment to ...

Discover a Swedish study, showing that total neoadjuvant treatment for locally advanced rectal cancer is effective in routine ...

Pancreatic cancer is a stubborn and difficult cancer to treat. In fact, it has the highest death rate of all major cancers. Now, researchers have found a new treatment protocol may help some people ...

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

A woman with breast cancer has slammed the phrasing the “good cancer”, saying the diagnosis turned her life “upside down”.

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

We spoke to 69-year-old Annie Ng, a retiree who was diagnosed with stage three breast cancer in 2021, and 49-year-old Janes ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...